AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2695819 — intervention group
Group type: EXPERIMENTAL
Intervention: Exfoliative cytology
Number of subjects: 0
Study 2695819 — intervention group
Group type: COMPARATOR
Intervention: Traditional bioptic examination
Number of subjects: 0
Study 16039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 to 6 mg lorazepam daily for four weeks
Number of subjects: 14
Study 16039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31375335 — intervention group
Group type: EXPERIMENTAL
Intervention: Second hand smoke (SHS) exposure
Number of subjects: 910
Study 29670416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Oxycodone
Number of subjects: 66
Study 29670416 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Morphine
Number of subjects: 66
Study 26032791 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported staging for the goal of eating a low-fat diet
Number of subjects: 2057
Study 26032791 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessed motivation and food frequency measures
Number of subjects: 2057
Study 23927572 — intervention group
Group type: EXPERIMENTAL
Intervention: Baker's yeast beta-glucan (BG)
Number of subjects: 242
Study 23927572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rice flour)
Number of subjects: 242
Study 22114294 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousing emotional stimuli
Number of subjects: 0
Study 22114294 — intervention group
Group type: COMPARATOR
Intervention: Low arousing neutral pictures
Number of subjects: 0
Study 18938119 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable poly[(R)‐3‐hydroxybutyrate] (PHB)
Number of subjects: 12
Study 18938119 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical epineural end‐to‐end suturing
Number of subjects: 12
Study 16974197 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 26
Study 16974197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 15205601 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha (6 microg/kg/week s.c. for 8 weeks, then 3 microg/kg/week s.c. maintenance)
Number of subjects: 40
Study 15205601 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha
Number of subjects: 40
Study 11258112 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD/AMC mode
Number of subjects: 48
Study 11258112 — intervention group
Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 48
Study 9249634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival retraction cord (aluminum sulfate-impregnated)
Number of subjects: 75
Study 9249634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival retraction cord (non-impregnated)
Number of subjects: 75
Study 9249634 — intervention group
Group type: COMPARATOR
Intervention: Root planing only (control group)
Number of subjects: 75
Study 8519045 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (750 mg or 1000 mg daily)
Number of subjects: 67
Study 8519045 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (150 mg daily)
Number of subjects: 67
Study 3755127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lysate
Number of subjects: 94
Study 3755127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 29847470 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% topical capsaicin patch
Number of subjects: 0
Study 29847470 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 27842943 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120mg/day
Number of subjects: 30
Study 24630545 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise class
Number of subjects: 75
Study 24630545 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual physiotherapy
Number of subjects: 75
Study 24630545 — intervention group
Group type: COMPARATOR
Intervention: Home exercises alone
Number of subjects: 75
Study 23075701 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg twice a day for 7 days (group A)
Number of subjects: 105
Study 23075701 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg twice a day for 7 days (group B)
Number of subjects: 105
Study 23075701 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg twice a day for 3 days each week for 2 weeks (group C)
Number of subjects: 105
Study 23075701 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study 19587296 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishment severity for perpetrators of hate crimes
Number of subjects: 0
Study 19587296 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim blame
Number of subjects: 0
Study 19587296 — intervention group
Group type: COMPARATOR
Intervention: Punishment severity for perpetrators of other types of crimes
Number of subjects: 0
Study 19587296 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim and perpetrator blame
Number of subjects: 0
Study 19088469 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with Lactobacillus johnsonii (La1)
Number of subjects: 71
Study 19088469 — intervention group
Group type: COMPARATOR
Intervention: Control formula without Lactobacillus johnsonii (La1)
Number of subjects: 71
Study 19088469 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 71
Study 19088469 — intervention group
Group type: EXPERIMENTAL
Intervention: All infants receiving La1
Number of subjects: 71
Study 19088469 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (La1, control formula, breastfed)
Number of subjects: 71
Study 16181164 — intervention group
Group type: EXPERIMENTAL
Intervention: FAME program (1-hour sessions, three sessions/week, for 19 weeks)
Number of subjects: 63
Study 16181164 — intervention group
Group type: COMPARATOR
Intervention: Seated upper extremity program (control group)
Number of subjects: 63
Study 16181164 — intervention group
Group type: EXPERIMENTAL
Intervention: FAME program
Number of subjects: 63
Study 12687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug I (propafenone, sotalol, disopyramide)
Number of subjects: 104
Study 12687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug II (second antiarrhythmic agent)
Number of subjects: 104
Study 12687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug III (amiodarone)
Number of subjects: 104
Study 12687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone during loading period
Number of subjects: 104
Study 12687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone after repeated CV
Number of subjects: 104
Study 12687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term amiodarone treatment
Number of subjects: 104
Study 12687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of amiodarone
Number of subjects: 104
Study 10419086 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil capsules (1.5-1.8 g DHA/d)
Number of subjects: 42
Study 10419086 — intervention group
Group type: COMPARATOR
Intervention: Control oil capsules (97% soybean oil + 3% fish oil)
Number of subjects: 42
Study 10419086 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil capsules (2 months)
Number of subjects: 42
Study 10419086 — intervention group
Group type: COMPARATOR
Intervention: Control oil capsules (2 months)
Number of subjects: 42
Study 10419086 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-sufficient diet (4 weeks)
Number of subjects: 42
Study 10419086 — intervention group
Group type: COMPARATOR
Intervention: DHA-deficient diet (4 weeks)
Number of subjects: 42
Study 7539874 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin therapy
Number of subjects: 40
Study 7539874 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 40
Study 2193119 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week chemohormonal treatment (CMFVP plus AT)
Number of subjects: 222
Study 2193119 — intervention group
Group type: COMPARATOR
Intervention: 36-week chemohormonal treatment (CMFVP)
Number of subjects: 222
Study 4935627 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizinic-acid-reduced liquorice 760 mg thrice daily for six weeks
Number of subjects: 90
Study 4935627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30975612 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNB + ROSE
Number of subjects: 800
Study 30975612 — intervention group
Group type: COMPARATOR
Intervention: EUS-FNB alone
Number of subjects: 800
Study 28234199 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person or Internet formats of administration for SES-SFP with men
Number of subjects: 569
Study 28234199 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person or Internet formats of administration for SES-SFV with women
Number of subjects: 569
Study 28234199 — intervention group
Group type: COMPARATOR
Intervention: SES-SFV with men
Number of subjects: 569
Study 28234199 — intervention group
Group type: COMPARATOR
Intervention: SES-SFP with women
Number of subjects: 569
Study 25830489 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV and DTPa
Number of subjects: 360
Study 25830489 — intervention group
Group type: COMPARATOR
Intervention: DTPa alone
Number of subjects: 360
Study 22895371 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load (HL) resistance exercise (70% peak torque)
Number of subjects: 8
Study 22895371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load (LL) resistance exercise (20% peak torque)
Number of subjects: 8
Study 22895371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow-restricted (LL(BFR)) resistance exercise (20% peak torque with an occlusive cuff inflated to 180 mm Hg)
Number of subjects: 8
Study 22089991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic image-guided injection
Number of subjects: 94
Study 22089991 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation-guided anatomic landmark injection
Number of subjects: 94
Study 19558483 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual oral brushing plus 0.12% chlorhexidine oral rinse administered twice per day
Number of subjects: 52
Study 19558483 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily manual oral brushing and upright feeding positioning
Number of subjects: 52
Study 16794647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexuality education in schools
Number of subjects: 250
Study 16794647 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of young people's sexual activity
Number of subjects: 250
Study 16794647 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching of contraception and safe abortion in schools
Number of subjects: 250
Study 15155893 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-film mammography (SFM)
Number of subjects: 25263
Study 15155893 — intervention group
Group type: COMPARATOR
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 25263
Study 11231036 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at a frequency of 0.2 Hz and intensity of 90% of motor threshold, delivered in four daily sessions with a train of 70 stimuli over 350 s
Number of subjects: 16
Study 11231036 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 9406983 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 12.5 mg
Number of subjects: 6
Study 9406983 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg
Number of subjects: 6
Study 9406983 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 37.5 mg
Number of subjects: 6
Study 9406983 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 6
Study 9406983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8218987 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 0.2 micrograms/kg ceruletide
Number of subjects: 105
Study 8218987 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 105
Study 3619095 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.86 mg/kg nalbuphine
Number of subjects: 16
Study 3619095 — intervention group
Group type: COMPARATOR
Intervention: 0.17 mg/kg butorphanol
Number of subjects: 16
Study 29048132 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided rhomboid major muscle injection
Number of subjects: 65
Study 29048132 — intervention group
Group type: COMPARATOR
Intervention: US-guided trapezius muscle injection
Number of subjects: 65
Study 27223304 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet (n = 22)
Number of subjects: 39
Study 27223304 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 39
Study 27223304 — intervention group
Group type: COMPARATOR
Intervention: Australian Guide to Healthy Eating (AGHE) diet (n = 17)
Number of subjects: 39
Study 23406268 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 implants
Number of subjects: 66
Study 23406268 — intervention group
Group type: COMPARATOR
Intervention: 6 implants
Number of subjects: 66
Study 23536140 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site rapid HIV testing at probation/parole office
Number of subjects: 1263
Study 23536140 — intervention group
Group type: COMPARATOR
Intervention: Referral for rapid HIV testing off site at a community HIV testing clinic
Number of subjects: 1263
Study 20463287 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 T DWI
Number of subjects: 135
Study 20463287 — intervention group
Group type: COMPARATOR
Intervention: 3.0 T DWI
Number of subjects: 135
Study 18646713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral intercostal nerve protection (Group B)
Number of subjects: 60
Study 18646713 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral intercostal nerve protection (Group U)
Number of subjects: 60
Study 18646713 — intervention group
Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy (Group C)
Number of subjects: 60
Study 16902771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 32
Study 16902771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15331798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab (bolus and infusion)
Number of subjects: 914
Study 15331798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab (bolus plus infusion)
Number of subjects: 914
Study 15331798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study 11410193 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab 5 mg/kg
Number of subjects: 33
Study 11410193 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab 10 mg/kg
Number of subjects: 33
Study 11410193 — intervention group
Group type: COMPARATOR
Intervention: intravenous placebo
Number of subjects: 33
Study 9243353 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylselegiline (10 mg)
Number of subjects: 10
Study 9243353 — intervention group
Group type: COMPARATOR
Intervention: Selegiline (10 mg)
Number of subjects: 10
Study 7684219 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 KIU/kg aprotinin in the CPB priming volume and 7,500 KIU/kg aprotinin intravenously each hour during CPB
Number of subjects: 27
Study 7684219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 27
Study 3610893 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral practice, assertiveness training, and social and contrived reinforcers (Group 1)
Number of subjects: 16
Study 3610893 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral practice, assertiveness training, and social and contrived reinforcers (Group 2)
Number of subjects: 16
Study 31755599 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) of the STN combined with best medical treatment
Number of subjects: 251
Study 31755599 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 251
Study 31150791 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1897
Study 31150791 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1897
Study 28327086 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention using a web tool
Number of subjects: 21
Study 25595527 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (coronary angiography performed) - 182 patients
Number of subjects: 313
Study 25595527 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (no coronary angiography) - 131 patients
Number of subjects: 313
Study 25595527 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 313
Study 23949975 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits by nurses or care managers every 6 months over 2 years
Number of subjects: 323
Study 23949975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 323
Study 21367726 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vP administered after priming with 2 doses of PCV7
Number of subjects: 348
Study 21367726 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of PCV7
Number of subjects: 348
Study 21367726 — intervention group
Group type: COMPARATOR
Intervention: 23vP
Number of subjects: 348
Study 19241799 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-needling
Number of subjects: 45
Study 19241799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% Lidocaine
Number of subjects: 45
Study 19241799 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 45
Study 16754728 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (n = 973)
Number of subjects: 19747
Study 16754728 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (n = 1010)
Number of subjects: 19747
Study 15449741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC concentration)
Number of subjects: 40
Study 15449741 — intervention group
Group type: COMPARATOR
Intervention: TIVA Propofol (6 mg/kg/h infusion)
Number of subjects: 40
Study 11445795 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral, family-based treatment
Number of subjects: 47
Study 11445795 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement in treatment
Number of subjects: 47
Study 9767362 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (15 mg per day)
Number of subjects: 24
Study 9767362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9767362 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 24
Study 7936334 — intervention group
Group type: EXPERIMENTAL
Intervention: FTTCA (Centella asiatica) 30 mg bid
Number of subjects: 87
Study 7936334 — intervention group
Group type: EXPERIMENTAL
Intervention: FTTCA (Centella asiatica) 60 mg bid
Number of subjects: 87
Study 7936334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 3068300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.i.d.)
Number of subjects: 63
Study 3068300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 29999572 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant-containing regimen
Number of subjects: 0
Study 26381165 — intervention group
Group type: COMPARATOR
Intervention: 80 mg simvastatin alone
Number of subjects: 30
Study 26381165 — intervention group
Group type: COMPARATOR
Intervention: 100 mg piragliatin alone
Number of subjects: 30
Study 26381165 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin and 100 mg piragliatin together
Number of subjects: 30
Study 24452825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy with adjunctive systemic amoxicillin and metronidazole (n=19)
Number of subjects: 40
Study 24452825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=21)
Number of subjects: 40
Study 24452825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (both groups)
Number of subjects: 40
Study 22673159 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted debriefing
Number of subjects: 30
Study 22673159 — intervention group
Group type: COMPARATOR
Intervention: Oral debriefing alone
Number of subjects: 30
Study 20829150 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified triangular flap
Number of subjects: 17
Study 20829150 — intervention group
Group type: COMPARATOR
Intervention: Buccal envelope flap (control)
Number of subjects: 17
Study 18164452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for chronic low back pain; specific dosage and duration not mentioned.
Number of subjects: 0
Study 18164452 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical interventions for chronic low back pain; specific interventions not detailed.
Number of subjects: 0
Study 15880022 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (Certican) in combination with reduced-exposure cyclosporine (CsA)
Number of subjects: 2
Study 15880022 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (Certican)
Number of subjects: 2
Study 12598264 — intervention group
Group type: COMPARATOR
Intervention: Morphine plus saline (MS; n = 114)
Number of subjects: 245
Study 12598264 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus ketamine (MK; n = 131)
Number of subjects: 245
Study 10367600 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (PER), 2 mg once daily
Number of subjects: 725
Study 10367600 — intervention group
Group type: COMPARATOR
Intervention: Captopril (CAP), 6.25 mg t.i.d.
Number of subjects: 725
Study 10367600 — intervention group
Group type: COMPARATOR
Intervention: Captopril (CAP)
Number of subjects: 725
Study 10367600 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (PER)
Number of subjects: 725
Study 8665256 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic posterior truncal vagotomy (PTV) and anterior linear gastrectomy (ALG)
Number of subjects: 136
Study 8665256 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic PTV with ALG
Number of subjects: 136
Study 1855277 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg prednimustine
Number of subjects: 12
Study 6869546 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal A (baked beans and polyethylene glycol (PEG 4000))
Number of subjects: 6